673 Stock Overview
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Cerevel Therapeutics Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.60 |
| 52 Week High | US$31.80 |
| 52 Week Low | US$20.60 |
| Beta | 1.55 |
| 1 Month Change | 0% |
| 3 Month Change | 0.85% |
| 1 Year Change | -6.35% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -12.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 673 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.8% | 1.1% |
| 1Y | -6.3% | -23.5% | 1.9% |
Return vs Industry: 673 exceeded the German Biotechs industry which returned -22.5% over the past year.
Return vs Market: 673 underperformed the German Market which returned 1% over the past year.
Price Volatility
| 673 volatility | |
|---|---|
| 673 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 673 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 673's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 334 | Ron Renaud | www.cerevel.com |
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company’s products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson’s disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder.
Cerevel Therapeutics Holdings, Inc. Fundamentals Summary
| 673 fundamental statistics | |
|---|---|
| Market cap | €6.88b |
| Earnings (TTM) | -€399.43m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-17.2x
P/E RatioIs 673 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 673 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$432.84m |
| Earnings | -US$432.84m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.38 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 66.7% |
How did 673 perform over the long term?
See historical performance and comparison